Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study

Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study

Submitted by admin on September 12, 2019 - 10:17am
Source: 
Pharmaceutical Business Review
News Tags: 
Roche
Tecentriq
clinical trials
non-small cell lung cancer
Headline: 
Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study
snippet: 


Roche announced that its lung cancer drug Tecentriq (atezolizumab) has significantly improved overall survival (OS) rate in the phase III IMpower110 study.

Do Not Allow Advertisers to Use My Personal information